1 December 2016

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Notice of AGM, posting of accounts and Directorate change

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and research reagents, confirms that the Annual Report and Accounts for the year ended 31 July 2016, the Notice of the Annual General Meeting and a Form of Proxy were posted to shareholders on 1 December 2016.

Craig Slater, the Group's Chief Operating Officer will not seek re-election at the forthcoming Annual General Meeting to be held on Friday 20 January 2017.  Accordingly, he will cease to be a board member from that date although will remain with the Company, overseeing the Animal Health business.

Dr. Trevor Nicholls, Non-executive Chairman of Avacta Group, commented:

"The Board would like to thank Craig for his significant contribution to the Group since he joined the Board in 2013. Craig will remain with the Group as Chief Operating Officer and continue to oversee Avacta Animal Health."

The Annual General Meeting is to be held on Friday 20 January 2017 at 10.00am GMT at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.

A copy of the Annual Report & Accounts and Notice of Annual General Meeting is available on the Company's website: www.avacta.com.

ENDS

Notes to Editors

For further information from Avacta Group plc, please contact:

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.